Table 1.
Patient characteristics.
| HNSCC | BC | ||
|---|---|---|---|
| gender | |||
| n | female | 4 | 8 |
| male | 12 | - | |
| age (years) | |||
| median (range) | female | 70 (32–81) | 48 (34–64) |
| male | 69 (58–79) | - | |
| stage of disease | |||
| n (%) | early stage | - | 4 (50%) |
| locally advanced | 1 (6%) | - | |
| recurrent/metastatic | 15 (94%) | 4 (50%) | |
| tumor site | |||
| n (%) | oral cavity | 8 (50%) | - |
| oropharynx | 3 (19%) | - | |
| hypopharynx | 3 (19%) | - | |
| other/breast | 2 (12%) | 8 (100%) | |
| metastatic sites | |||
| n (%) | none | 1 (0.06%) | 4 (50%) |
| regional | 3 (25%) | 3 (38%) | |
| distant | 12 (75%) | 1(12%) | |
| CTCpositive cases (≥ 3 CTCs) | |||
| n (%) | 7 (44%) | 6 (75%) | |
| CTC numbers | |||
| median | 15 | 14 | |
| range | 6–30 | 9–27 | |
| PD-L1positive cases | |||
| n (%) | 4 (57%) | 4 (67%) | |
| PD-L1positive cells | |||
| median (n) | 6 | 2 | |
| range (n) | 3–30 | 1–6 | |
| % of PD-L1positive CTCs in entire CTC population | median (%) range (%) |
100% 56%–100% |
15% 4%–25% |